Pipeline
R&D PIPELINE
We established a diversified and comprehensive R&D pipeline covering oncology, autoimmune diseases, pain management, cardiovascular diseases, metabolic diseases, infectious diseases, respiratory system diseases, hematological diseases, neurological diseases, ophthalmology, etc.
Major R&D Pipelines
-
18
New Molecular Entity drugs marketed in China
-
4
Other innovative drugs marketed in China
-
90
+
In-House Innovative Pharmaceuticals under Clinical Development
-
~
400
Ongoing Clinical Studies
-
20
+
Ongoing International Clinical Studies
*By January 6, 2025
Oncology
临床前
Phase I
-
HRS-9815
PSMA Nuclear Medicine
Prostate cancer diagnosis
Single AgentPhase I
-
HRS-3738
CRBN-E3
Multiple myeloma and non-Hodgkin's lymphoma (NHL)
Single Agent/Combination TherapyPhase I
-
HRS-1358
ER-PROTAC
Advanced breast cancer
Combination Therapy (dalpiciclib)Phase I
-
SHR-2017
Prevention of bone-related events in solid tumor with bone metastases and multiple myeloma
Single AgentPhase I
-
SHR-2005
Bladder caner
Single AgentPhase I
-
SHR-9539
Multiple myeloma
Single AgentPhase I
-
SHR-4849
DLL3 ADC
Advanced malignant solid tumors
Single AgentPhase I
-
HRS-6208
Advanced malignant solid tumors
Single AgentPhase I
-
HRS-3802
Advanced malignant solid tumors
Single AgentPhase I
-
SHR-7787
Advanced malignant solid tumors
Single AgentPhase I
-
SHR-3821
Advanced malignant solid tumors
Single AgentPhase I
-
HRS-4508
Advanced malignant solid tumors
Single AgentPhase I
-
SHR-4394
Prostate cancer
Single AgentPhase I
-
SHR-1681
Advanced malignant solid tumors
Single AgentPhase I
-
HRS-7058
KRAS G12C
Advanced solid tumors
Single AgentPhase I
Phase II
-
HRS-4357
PSMA Nuclear Medicine
Metastatic castration-resistant prostate cancer
Single AgentPhase II
-
HRS-1167
PARP1
Recurrent ovarian cancer
Combination Therapy (bevacizumab)Phase II
Advanced prostate cancer
Combination TherapyPhase II
Advanced solid tumors
Single AgentPhase I
-
SHR-4602
HER2 ADC (Next-gen)
HER2-expressing or -mutated advanced solid tumors
Combination TherapyPhase II
HER2-expressing or -mutated solid tumors
Single AgentPhase I
-
SHR-1501
IL-15
Non-muscle invasive bladder cancer
Combination Therapy (BCG bladder perfusion)Phase II
-
SHR-A1912
CD79b ADC
B-cell non-Hodgkin lymphoma
Combination TherapyPhase II
B-cell non-Hodgkin lymphoma
Single AgentPhase I
USB-cell lymphoma
Single AgentPhase I
-
HRS2398
ATR
Advanced solid tumors
Combination TherapyPhase II
-
HRS-8080
SERD
ER-positive, HER2-negative unresectable or metastatic breast cancer
Combination Therapy (dalpiciclib)Phase II
Advanced breast cancer
Single Agent/Combination TherapyPhase I
-
HRS-4642
KRAS G12D
Advanced solid tumors with KRAS G12D mutations
Combination TherapyPhase II
Advanced solid tumors
Single AgentPhase I
-
HRS-6209
CDK4
Advanced breast cancer
Combination Therapy (HRS-8080/HRS-1358)Phase II
Advanced solid tumors
Single AgentPhase I
-
SHR-9839
Advanced solid tumors
Combination TherapyPhase II
Advanced solid tumors
Single AgentPhase I
-
HRS-2189
KAT6
Advanced breast cancer
Combination TherapyPhase II
Advanced malignant tumors
Single AgentPhase I
-
HRS-5041
AR-PROTAC
Advanced prostate cancer
Combination TherapyPhase II
Metastatic castration-resistant prostate cancer
Single AgentPhase I
Australia, China -
SHR-1826
c-Met ADC
Advanced solid tumors
Combination TherapyPhase II
Advanced malignant solid tumors
Single AgentPhase I
Phase III
-
SHR-A2009
HER3 ADC
EGFR-mutated advanced or metastatic non-small cell lung cancer that has failed EGFR TK therapy
Single AgentPhase III
Advanced solid tumors
Combination TherapyPhase II
Advanced or metastatic solid tumors
Single AgentPhase I
Advanced solid tumors
Single AgentPhase I
Japan and Korea -
SHR-A1921
TROP2 ADC
Platinum-sensitive recurrent epithelial ovarian cancer
Single Agent or Combination Therapy with carboplatinPhase III
Platinum-resistant recurrent epithelial ovarian cancer
Single AgentPhase III
Advanced solid tumors
Single AgentPhase II
US, AustraliaAdvanced solid tumors
Combination TherapyPhase II
-
SHR-A1904
Claudin 18.2 ADC
2nd-line CLDN18.2-positive advanced gastric cancer or gastroesophageal junction adenocarcinoma
Single AgentPhase III
CLDN18.2-positive advanced solid tumors
Combination Therapy (adebrelimab)Phase III
Advanced pancreatic cancer
Single AgentPhase I
Advanced solid tumors
Single AgentPhase I
US, Australia, China -
SHR-A2102
Nectin-4 ADC
2nd/3rd-line locally advanced or metastatic urothelial carcinoma
Single AgentPhase III
Advanced solid tumors
Single AgentPhase II
USAdvanced gynecologic malignancies
Single AgentPhase II
Locally advanced or metastatic non-small cell lung cancer
Combination TherapyPhase II
Advanced urothelial carcinoma
Combination Therapy (adebrelimab)Phase II
Locally advanced or metastatic esophageal cancer
Combination Therapy (adebrelimab)Phase II
Advanced solid tumors
Single AgentPhase I
NDA/BLA Filed
-
SHR2554
EZH2
Relapsed and refractory peripheral T-cell lymphoma
Single AgentNDA/BLA Filed
T-cell lymphoma
Combination TherapyPhase II
Relapsed and refractory follicular lymphoma
Single AgentPhase II
Refractory/relapsed T-cell lymphoma
Single AgentPhase I
-
SHR-1701
PD-L1/TGF-β
1st-line advanced or metastatic gastric cancer (GC) or gastroesophageal junction cancer
Combination Therapy (chemotherapy)NDA/BLA Filed
Advanced solid tumors
Single AgentPhase I
Australia -
SHR-A1811
HER2 ADC
2nd-line and subsequent locally advanced or metastatic HER2-mutated adult non-small cell lung cancer
Single AgentNDA/BLA Filed
HER2-positive metastatic breast cancer
Single AgentPhase III
HER2-low recurrent/metastatic breast cancer
Single AgentPhase III
Adjuvant therapy for HER2-positive breast cancer
Single AgentPhase III
HER2-positive recurrent or metastatic breast cancer
Combination TherapyPhase III
3rd-line HER2-positive advanced colorectal cancer
Single AgentPhase III
1st-line treatment for HER2-mutated advanced or metastatic non-small cell lung cancer
Single AgentPhase III
Advanced solid tumors with HER2 expression
Combination Therapy (fuzuloparib)Phase II
HER2-low metastatic or unresectable breast cancer
Combination TherapyPhase II
HER2-expressing gynecological malignancies
Single AgentPhase II
HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma
Combination Therapy (adebrelimab+chemotherapy)Phase II
1st-line HER2 mutated, amplified, or overexpressed advanced non-small cell lung cancer
Combination Therapy (pyrotinib/adebrelimab)Phase II
Locally advanced unresectable or recurrent metastatic biliary tract cancer with HER2 expression/amplification
Single AgentPhase II
Gastric cancer or adenocarcinoma of the gastroesophageal junction and colorectal cancer
Single AgentPhase I
Advanced solid tumors
Single AgentPhase I
US, Australia, Asia Pacific (including China) -
HR20013
NK-1RA in combination with 5-HT3RA
Prevention of highly emetogenic chemotherapy-induced nausea and vomiting
Single Agent (FDC)NDA/BLA Filed
Prevention of nausea and vomiting caused by antineoplastic drugs with moderate risk of vomiting
Single Agent (FDC)Phase III
Marketed
-
Apatinib
VEGFR
HER2-negative metastatic breast cancer adult patients with germline BRCA mutations
Combination Therapy (fuzuloparib)Marketed
Advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma progressed or relapsed after at least 2Ls of systematic chemotherapy
Single AgentMarketed
Advanced hepatocellular carcinoma failed or intolerable after at least first-line systemic therapy
Single AgentMarketed
1st-line unresectable or metastatic hepatocellular carcinoma
Combination Therapy (camrelizumab)Marketed
1st-line unresectable or metastatic hepatocellular carcinoma
Combination Therapy (camrelizumab)NDA/BLA Filed
US, Europe, and Asia Pacific (including China)Unresectable hepatocellular carcinoma
Combination Therapy (TACE+camrelizumab)Phase III
-
Pyrotinib
HER1, HER2, and HER4
Relapsed or metastatic advanced HER2-positive breast cancer patients without previous HER2 treatment
Combination Therapy (trastuzumab+docetaxel)Marketed
Relapsed or metastatic HER2-positive breast cancer with previous trastuzumab treatment
Combination Therapy (capecitabine)Marketed
Neoadjuvant treatment for early or locally advanced HER2-positive breast cancer
Combination Therapy (trastuzumab+docetaxel)Marketed
Extended adjuvant therapy for HER2-positive breast cancer
Single AgentPhase III
Advanced non-squamous non-small cell lung cancer with HER2 mutation
Single AgentPhase III
US, Europe, and Asia Pacific (including China) -
Camrelizumab
PD-1
Relapsed and refractory classical Hodgkin lymphoma after at least two systematic therapies
Single AgentMarketed
Advanced hepatocellular carcinoma after sorafenib and/or lenvatinib and/or oxaliplatin-containing chemotherapy treatments
Single AgentMarketed
1st-line unresectable locally advanced or metastatic EGFR-mut negative ALK-negative NSCLC
Combination Therapy (pemetrexed+carboplatin)Marketed
Locally advanced or metastatic esophageal adenocarcinoma progressed after or intolerable to 1st-line treatment
Single AgentMarketed
Advanced nasopharyngeal carcinoma progressed after or intolerable to 2nd-line+ chemotherapy
Single AgentMarketed
1st-line locally relapsed or metastatic nasopharyngeal carcinoma
Combination Therapy (cisplatin+gemcitabine)Marketed
1st-line unresectable locally advanced/relapsed or metastatic esophageal squamous cell carcinoma
Combination Therapy (cisplatin+paclitaxel)Marketed
1st-line locally advanced/metastatic squamous non-small cell lung cancer
Combination Therapy (carboplatin+paclitaxel)Marketed
1st-line unresectable or metastatic hepatocellular carcinoma
Combination Therapy (apatinib)Marketed
Recurrent metastatic cervical cancer
Combination Therapy (famitinib)NDA/BLA Filed
1st-line advanced hepatocellular carcinoma
Combination Therapy (apatinib)NDA/BLA Filed
US, Europe, and Asia Pacific (including China)Relapsed and refractory classical Hodgkin lymphoma
Single AgentPhase III
Unresectable hepatocellular carcinoma
Combination Therapy (TACE+apatinib)Phase III
Unresectable locally advanced esophageal cancer
Combination TherapyPhase III
1st-line advanced cervical cancer
Combination Therapy (famitinib)Phase III
-
fuzuloparib
PARP1/2
Maintenance therapy for adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who achieve complete or partial remission with 1st-line platinum-based chemotherapy
Single AgentMarketed
Metastatic HER2-negative breast cancer with BRCA1/2 mutation
Single Agent/Combination Therapy (apatinib)Marketed
Recurrent platinum-sensitive gBRCA-mut ovarian carcinoma, fallopian tube carcinoma, or primary peritoneal carcinoma after 2nd-line+ chemotherapy
Single AgentMarketed
Maintenance therapy for platinum-sensitive recurrent epithelial ovarian carcinoma, fallopian tube carcinoma, or primary peritoneal carcinoma after platinum-containing chemotherapy
Single AgentMarketed
Metastatic castration-resistant prostate cancer
Combination Therapy (abiraterone)Phase III
US, Europe, and Asia Pacific (including China) -
Dalpiciclib
CDK4/6
Relapsed or metastatic HR-positive HER2-negative breast cancer progressed after endocrine therapy
Combination Therapy (fulvestrant)Marketed
Initial endocrine therapy for locally advanced or metastatic HR-positive HER2-negative breast cancer
Combination Therapy (aromatase inhibitor)Marketed
Adjuvant therapy for HR-positive, HER2-negative breast cancer
Combination TherapyPhase III
-
Rezvilutamide
AR
Metastatic hormone sensitive prostate cancer (mHSPC) with high tumor burden
Single AgentMarketed
Metastatic hormone-sensitive prostate cancer
Single AgentPhase III
Europe, China -
Adebrelimab
PD-L1
1st-line extensive stage small cell lung cancer (ES-SCLC)
Combination Therapy (carboplatin + etoposide)Marketed
1st-line therapy for limited-stage small cell lung cancer
Combination TherapyPhase III
Perioperative treatment of resectable stage II or III non-small cell lung cancer
Combination TherapyPhase III
1st-line therapy for STK11/KEAP1/KRAS mutated advanced or metastatic non-squamous non-small cell lung cancer
Combination Therapy (SHR-8068+platinum-containing doublet chemotherapy)Phase III
Advanced hepatocellular carcinoma
Combination Therapy (SHR-8068+bevacizumab)Phase III
Advanced non-small cell lung cancer
Combination Therapy (SHR-8068+platinum-containing chemotherapy)Phase II
1st-line advanced biliary tract cancer
Combination Therapy (SHR-8068+platinum-containing chemotherapy)Phase II
Advanced gastric cancer and esophageal cancer
Combination Therapy (SHR-8068+platinum-containing chemotherapy)Phase II
Locally advanced cervical cancer
Combination TherapyPhase II
-
Hetrombopag
TPO-R
Adult chronic primary immune thrombocytopenia who have not responded well to glucocorticoids, immunoglobulins, etc
Single AgentMarketed
Severe aplastic anemia who do not respond well to immunosuppressive therapy
Single AgentMarketed
Primary treatment of severe aplastic anemia
Combination TherapyNDA/BLA Filed
Chemotherapy-induced thrombocytopenia
Single AgentPhase III
US, Australia, Europe, and ChinaChildren with immune thrombocytopenia (ITP)
Single AgentPhase III
Chronic liver disease with thrombocytopenia with invasive procedures or surgeries
Single AgentPhase III
Primary treatment of non-severe aplastic anemia
Combination therapyPhase II
-
Linperlisib
PI3Kδ
Refractory/relapsed follicular lymphoma in adult patients after 2nd-line+ systematic treatment
Single AgentMarketed
-
Mecapegfilgrastim
G-CSF
Chemotherapy-induced neutropenia in adults with malignant cancers
Single AgentMarketed
Metabolic And Cardiovascular Diseases
临床前
Phase I
-
HRS-5346
Lipoprotein disorders
Single AgentPhase I
-
HRS-7249
Hyperlipidemia
Single AgentPhase I
-
HRS-5632
Lipoprotein disorders
Single AgentPhase I
-
HRS-6934
Heart failure
Single AgentPhase I
-
HRS-9563
Hypertension
Single AgentPhase I
-
HRS-4729
GLP-1/GIP/GCG
Overweight or obesity
Single AgentPhase I
-
HRS-9057
Fluid retention due to heart failure
Single AgentPhase I
Phase II
-
SHR-3167
Diabetes mellitus
Single AgentPhase II
-
SHR-2004
FXI
Prevention of venous thromboembolism after knee arthroplasty
Single AgentPhase II
Prevention of postoperative venous thromboembolism in patients undergoing ovarian cancer surgery
Single AgentPhase II
Prevent the risk of stroke or systemic embolism in patients with ventricular fibrillation
Single AgentPhase I
-
HRS-1893
Obstructive hypertrophic cardiomyopathy
Single AgentPhase II
-
HRS-1780
Mineralocorticoid receptors
Chronic kidney disease
Single AgentPhase II
Phase III
-
INS068
Insulin
Type 2 diabetes mellitus
Single AgentPhase III
-
HR17031
Insulin/GLP-1
Type 2 diabetes mellitus
Single Agent (FDC)Phase III
-
HRS-7535
GLP-1 (oral)
Type 2 diabetes mellitus
Single AgentPhase III
Overweight or obesity
Single AgentPhase II
Diabetic kidney disease
Single AgentPhase II
-
HRS9531
GLP-1/GIP
Overweight or obesity
Single AgentPhase III
Type 2 diabetes mellitus
Single AgentPhase III
Obesity with heart failure
Single AgentPhase II
Obesity with obstructive sleep apnea
Single AgentPhase II
Obesity with polycystic ovary syndrome
Single AgentPhase II
Weight management and type 2 diabetes mellitus
Single Agent (tablet)Phase I
-
SHR-1918
ANGPTL3
Homozygous familial hypercholesterolemia
Single AgentPhase III
Hyperlipidemia
Single AgentPhase II
-
SHR4640
URAT1
Primary gout with hyperuricemia
Single AgentPhase III
Hyperuricemia in patients with gout
Combination Therapy (febuxostat)Phase II
-
SHR6508
CaSR
Secondary hyperparathyroidism in patients on maintenance hemodialysis with chronic kidney disease
Single AgentPhase III
NDA/BLA Filed
-
HRX0701
DPP-IV/Metformin
Type 2 diabetes mellitus
Single Agent (FDC)NDA/BLA Filed
Marketed
-
Henagliflozin
SGLT-2
Type 2 diabetes mellitus
Combination Therapy (metformin+retagliptin)Marketed
Improve glycemic control in adults with type 2 diabetes mellitus
Single Agent/Combination Therapy (metformin)Marketed
Chronic kidney disease
Single AgentPhase II
-
Retagliptin
DPP-IV
Type 2 diabetes mellitus
Single Agent/Combination Therapy (metformin)Marketed
-
Recaticimab
PCSK9
Adults with primary hypercholesterolemia (including heterozygous familial and non-familial hypercholesterolemia) and mixed dyslipidemia who are unable to achieve low-density lipoprotein cholesterol (LDL-C) goals despite moderate or higher doses of statins, or in combination with statins and other lipid-lowering therapies on the basis of dietary control; or as a single agent Adult patients with nonfamilial hypercholesterolemia and mixed dyslipidemia to reduce low-density lipoprotein cholesterol (
Single AgentMarketed
Immunological And Respiratory Diseases
临床前
Phase I
-
HRS-7085
Inflammatory bowel disease (healthy volunteers)
Single AgentPhase I
AustraliaInflammatory bowel disease
Single AgentPhase I
-
HRS-9821
PDE3/4
Chronic obstructive pulmonary disease (COPD)
Single AgentPhase I
-
RSS0343
Non-cystic fibrosis bronchiectasis
Single AgentPhase I
-
SHR-4597
Asthma
Single AgentPhase I
-
HRS-9813
Idiopathic pulmonary fibrosis
Single AgentPhase I
-
RSS0393
Psoriasis
Single AgentPhase I
-
SHR-1139
Psoriasis
Single AgentPhase I
-
SHR-2173
Systematic lupus erythematosis
Single AgentPhase I
Phase II
-
SHR-1905
TSLP
Asthma
Single AgentPhase II
Chronic rhinosinusitis with nasal polyp (CRSwNP)
Single AgentPhase II
Chronic obstructive pulmonary disease
Single AgentPhase I
Asthma (healthy volunteers)
Single AgentPhase I
Australia
Phase III
-
SHR-1819
IL-4Rα
Atopic dermatitis
Single AgentPhase III
Prurigo nodularis
Single AgentPhase III
Chronic spontaneous urticaria
Single AgentPhase II
Atopic dermatitis in children/adolescents
Single AgentPhase I
Atopic dermatitis (healthy volunteers)
Single AgentPhase I
China, Australia -
SHR-1703
IL-5
Eosinophilic asthma
Single AgentPhase III
Eosinophilic granulomatosis with polyangiitis
Single AgentPhase III
-
HRS-5965
Factor B
Untreated paroxysmal nocturnal hemoglobinuria
Single AgentPhase III
Paroxysmal nocturnal hemoglobinuria treated with C5 antibody
Single AgentPhase III
IgA nephropathy
Single AgentPhase II
NDA/BLA Filed
-
SHR0302
JAK1
Ankylosing spondylitis
Single AgentNDA/BLA Filed
Moderate-to-severe active rheumatoid arthritis
Single AgentNDA/BLA Filed
Moderate-to-severe atopic dermatitis
Single AgentNDA/BLA Filed
China, CanadaAlopecia
Single AgentNDA/BLA Filed
Psoriatic arthritis
Single AgentPhase III
Active radiologically negative mid-axis spondyloarthritis
Single AgentPhase III
Mild-to-moderate atopic dermatitis
Single Agent (ointment)Phase III
Ulcerative colitis
Single AgentPhase III
US, Europe, ChinaVitiligo
Single Agent (alkaline gel)Phase I
Marketed
-
Vunakizumab
IL-17A
Adults with moderate to severe plaque psoriasis who are receiving systemic therapy or phototherapy
Single AgentMarketed
Active ankylosing spondylitis in adults
Single AgentNDA/BLA Filed
Moderate-to-severe chronic plaque psoriasis in children and adolescents
Single AgentPhase III
Psoriatic arthritis
Single AgentPhase III
-
Imrecoxib
COX2
Osteoarthritis-related pain
Single AgentMarketed
Neuroscience
临床前
Phase II
-
SHR-1707
A-beta
Alzheimer's disease
Single AgentPhase II
Alzheimer's disease
Single AgentPhase I
Australia -
HRS8179
SUR1
Severe cerebral edema after massive ischemic stroke
Single AgentPhase II
-
HRS-9231
MRI of the brain and whole body
Single AgentPhase II
MRI testing
Single AgentPhase I
Australia
Phase III
NDA/BLA Filed
Marketed
-
Tegileridine fumarate
MOR
Post-operative analgesia for abdominal surgeries
Single AgentMarketed
Moderate to severe pain after orthopedic surgery
Single AgentNDA/BLA Filed
-
Remimazolam
GABAa
Sedation and anesthesia in non-endotracheal intubation procedures/procedures, general anesthesia induction and maintenance
Single AgentMarketed
ICU sedation with mechanical ventilation
Single AgentPhase III
Others
临床前
Phase I
-
HRS-2183
Severe infections caused by gram-negative bacteria
Single AgentPhase I
Phase II
-
HRS9432
Anidulafungin derivatives
Candidemia or invasive candidiasis
Single AgentPhase II
-
HRS-5635
HBV siRNA
Chronic hepatitis B
Single AgentPhase II
-
HRS5580
NK1
Prevent postoperative nausea and vomiting
Single AgentPhase II
Phase III
-
HRS-8427
Cefiderocol derivatives
Complicated urinary tract infection
Single AgentPhase III
Pulmonary infection
Single AgentPhase I
-
SHR7280
GnRH
Controlled ovarian hyperstimulation
Single AgentPhase III
NDA/BLA Filed
-
SHR8058
Perfluorohexyloctane
Dry eye syndrome associated with meibomian gland dysfunction
Single AgentNDA/BLA Filed
Marketed
-
Oteseconazole
CYP51
Severe vulvovaginal candidiasis
Single AgentMarketed